schizophrenia
Conditions
Sponsors
Guangzhou Women and Children's Medical Center
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Subjects meeting the DSM-V, ICD-10 criteria for schizophrenia; 2. Male or female Chinese subjects aged 18-65 years; 3. Subjects who are hospitalized (in-hospital patients) at screening phase, and can remain in hospital during study period; 4. Subjects who are in the phrase of acute schizophrenia with a score from 70 to 120 on the PANSS scale and are appropriate to receive sevoflurane inhalation according to the investigators judgment. 5. Subjects with a minimum score of 14 on the PANSS -excited component(PANSS-EC) score with at least 1 item no less than 4.(P4. excited, P7. Hostility, G4. Physical tension, G8. Uncooperative, G14. Impulse control disorder); 6. Evidence of a subject (or a legal representative) signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study and are willing to participate in it.
Exclusion criteria
Exclusion criteria: 1. Acute phrase due to delirium, seizures, affective psychosis, poisoning, or substance abuse withdrawal reactions; 2. Relevent history or current presence of any cardiovascular, respiratory, neurological, renal, hepatic, endocrine, immunologic or other systemic disease; 3. Confirmed clinically significant abnormal laboratory values; 4. Clinically significant ECG abnormality; 5. Subjects with a history of QTc prolongation or a pre-drug QTc of 450 msec or greater; 6. Subjects with serum K+ or Mg2+ beyond the normal range; 7. A history of malignant syndrome or tardive dyskinesia history; 8. Pregnant or lactating women; 9. Monoamine oxidase antidepressants were administered prior to the study in 2 weeks; 10. Long-acting antipsychotics were administered prior to screening in 1 month; 11. Participation in other studies within the last 30 days before the current study begins and /or during study participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PANSS score; | — |
Secondary
| Measure | Time frame |
|---|---|
| BPRS;SCL-90;Drug Side Effects Scale;BRMS;MCCB;SAS;SDS;HAMA;HAMD;GCI-I; | — |
Countries
China
Contacts
Public ContactTianyun Zhao
Guangzhou Women and Children's Medical Center
Outcome results
None listed